Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38937 Aterian, Inc. (Exact name of registrant as specified in its charter) Delaware 83-1739858 (State or other jurisdiction of incorporation or o ...

Financial Performance - Forte Biosciences reported a net loss per share of $(12.17) for the year ended December 31, 2024, compared to $(24.92) for 2023, indicating an improvement in loss per share by 51.1%[6]. - Forte's accumulated deficit increased to $(153.998) million in 2024 from $(118.520) million in 2023, reflecting a rise of 29.9% in accumulated losses[8]. Expenses - Research and development expenses decreased to $21.2 million in 2024 from $21.9 million in 2023, a reduction of $0.7 million, primarily due to a $7.0 million decrease in manufacturing expenses[4]. - General and administrative expenses increased to $15.4 million in 2024, up from $10.6 million in 2023, reflecting a rise of $4.8 million mainly due to higher professional and legal expenses[5]. Cash and Assets - Forte ended 2024 with $58.4 million in cash, cash equivalents, and short-term investments, down from $37.1 million in cash and cash equivalents at the end of 2023[6]. - Total current assets increased to $61.3 million as of December 31, 2024, compared to $38.3 million in 2023, reflecting a growth of 60.0%[8]. Liabilities - Total liabilities rose to $9.1 million in 2024 from $3.7 million in 2023, an increase of 147.0%[8]. Clinical Trials - The company initiated a celiac patient trial for FB102, with nearly half of the patients having completed both dosing and gluten challenge, and topline results expected in Q2 2025[3]. - The company anticipates dosing the first patient in the FB102 vitiligo trial shortly, indicating ongoing commitment to expanding its clinical programs[3]. Fundraising - Forte raised $53.0 million in gross proceeds from an over-subscribed private placement in November 2024, enhancing its financial position[6].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40775 ALPHA MODUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Securities regis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40775 ALPHA MODUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other ...

Exhibit 99.1 Investor Relations Contact: Liz Morali (408) 986-7977 liz_morali@amat.com Media Contact: Ricky Gradwohl (408) 235-4676 ricky_gradwohl@amat.com APPLIED MATERIALS ANNOUNCES SECOND QUARTER 2025 RESULTS "We delivered strong performance in our second fiscal quarter with seven percent year-over-year revenue growth, record earnings per share and shareholder distributions of nearly $2 billion," said Brice Hill, Senior Vice President and CFO. "Despite the dynamic economic and trade environment, we have ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 1-5103 BARNWELL INDUSTRIES, INC. 1100 Alakea Street, Suite 500, Honolulu, Hawaii 96813 (Address of principal executive offices) (Zip code) (Exact name of registrant as specified ...

Origin Materials, Inc. Reports Operating and Financial Results for First Quarter 2025 – Announces Signed Strategic Customer Agreement with Major Packaging Company for the Development of Large Format PET Closures for the Ready to Drink, Wine, and Spirits Market – – CapFormers Five Through Eight Now Estimated to Begin PET Cap Production in 1H 2026 – WEST SACRAMENTO, CA., May 15, 2025 – Origin Materials, Inc. ("Origin," "Origin Materials," or the "Company") (Nasdaq: ORGN, ORGNW), a technology company with a mi ...

Exhibit 99.1 AleAnna, Inc. Reports First Quarter 2025 Results Longanesi First Gas Sales Have Been Achieved First Quarter 2025 and Recent Company Highlights: DALLAS – May 15, 2025 – AleAnna, Inc. ("AleAnna" or "the Company") (NASDAQ: ANNA) today announced financial results for the first quarter of 2025. While revenue from the Longanesi field production was not recognized during the quarter, in May 2025 we achieved first sales and the Company expects to report revenue from the Longanesi field as a part of sec ...

Exhibit 99.1 AleAnna, Inc. Reports First Quarter 2025 Results Longanesi First Gas Sales Have Been Achieved First Quarter 2025 and Recent Company Highlights: DALLAS – May 15, 2025 – AleAnna, Inc. ("AleAnna" or "the Company") (NASDAQ: ANNA) today announced financial results for the first quarter of 2025. While revenue from the Longanesi field production was not recognized during the quarter, in May 2025 we achieved first sales and the Company expects to report revenue from the Longanesi field as a part of sec ...

Financial Performance - Cash, cash equivalents, and marketable securities totaled $258 million as of March 31, 2025[1] - Revenue from collaboration with Chiesi for the quarter ended March 31, 2025, was $9.9 million, including $6.6 million of cost reimbursement revenue[8] - Research and Development (R&D) expenses for the quarter were $38.0 million, compared to $32.4 million for the same period in 2024, representing an increase of 20.5%[8] - General and Administrative (G&A) expenses for the quarter were $8.7 million, a decrease from $9.6 million for the same period in 2024[8] - Net loss for the quarter was $36.6 million, or $0.16 basic net loss per share, compared to a net loss of $41.9 million, or $0.19 basic net loss per share, for the same period in 2024[8] Clinical Trials - Enrollment for the ongoing registrational Phase 3 PROSERA Study in PAH patients is expected to complete in early June 2025, with over 350 patients anticipated[1] - Topline results from the PROSERA Phase 3 Study are expected to be announced in February 2026[1] - The Phase 3 SERANATA Study in PH-ILD patients is expected to activate clinical sites in the fourth quarter of 2025, with approximately 480 patients to be randomized[7] - The PROSERA Study has enrolled 343 patients to date, with a target of 350 participants[6] - The primary endpoint of the PROSERA Study is the change in six-minute walk distance (6MWD) from baseline compared to placebo at week 24[6]